BioSpace News Archive

Altamira Therapeutics Ltd., a company dedicated to developing therapeutics that address important unmet medical needs, issued a Letter to Shareholders providing highlights of the Company’s recent achievements and its 2022 outlook.

Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.

Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent for claims that cover Clarus’ oral testosterone replacement product, JATENZO (testosterone undecanoate).

Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2022.

Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche Laboratories executive, Tammy Reilly, to Sorrento’s board of directors.

CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).

Fresenius Kabi announced that Brandee Pappalardo, Ph.D., M.P.H. has joined the company as senior vice president and Chief Medical Officer for North America.

C2N Diagnostics, a leader in advanced brain health diagnostics that offers the PrecivityAD™ blood test as an aid to Alzheimer’s disease diagnosis, today announced its latest innovative offering for enhancing care in brain health: a high-resolution mass spectrometry-based plasma tau multi-analyte assay (p-tau MAA) for Research Use Only (RUO).

Vertex Pharmaceuticals Incorporated announced that Suketu Upadhyay has been elected to its board of directors as an independent director.

The Annual General Meeting of Spago Nanomedical AB was held , May 18, 2022, at which the AGM resolved to approve the income statement and balance sheet for 2021 and discharge the Board members and the CEO from liability for the financial year 2021.